Lixte reports favorable interim results for LB-100 plus dostarlimab ovarian cancer trial

PUBT·04/13/2026 12:06:23

Listen to the news

Lixte Biotechnology reported preliminary results already presented at Society of Gynecological Cancer conference held April 10-13, 2026 in San Juan for a trial combining LB-100 with GSK’s PD-1 drug Dostarlimab in ovarian clear cell carcinoma.
Interim readout showed an acceptable safety profile and signs of disease control, supporting continued development of combination regimen.
Enrollment reached 21 planned participants, with 20 included in interim efficacy analysis.
Program is expanding with an additional 21-patient cohort now enrolling at higher LB-100 exposure to further test activity in patients lacking genetic reduction in PP2A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130800PRIMZONEFULLFEED9688034) on April 13, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English